Abstract In the present study, a novel magnetic organosilica supported Pd-Schiff base complex (Fe₃O₄@SiO₂/Si(CH₂)₃NH/HMPO/Pd(OAc)₂) was prepared. The nanocatalyst were synthesized using Fe₃O₄@SiO₂ core–shell nanoparticles and functionalized with 3-chloropropyltrimethoxysilane (CPTMS) as Fe₃O₄@SiO₂@Cl. The Schiff base ligand was synthesized by reaction of 5-hydroxypicolinaldehyde with hydrazine to produce of (hydrazineylidenemethyl)pyridin-3-ol (HMPO), then palladium acetate was added to produce of Schiff-base-Pd(II) complex. The catalyst was characterized thoroughly by FT-IR, XRD, SEM, TEM, VSM, EDX, TGA, SEM image of elemental maps and ICP analyses. Its catalytic activity was assessed in the synthesis of 12-aryl- 8,9,10,12-tetrahydrobenzo[a]xanthene-11-one, 14-aryl-14H- hexahydro-11H-benzo[a]xanthen-11-one and chromeno[2,3-b]pyridine-3-carbonitrile derivatives through a one-pot condensation of dimedone or malononitrile, naphthols, and aryl aldehydes in EtOH/H₂O. The excellent yield of products, easy work-up, column-free, short reaction time, and facility of reusability by an external magnet are other important advantages of this methodology.
No takes yet. Share an insight, caveat, or question.
Heravi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: